Skip to main content

Table 3 Linear regression of biomarker levels in patients with vascular malformations compared with controls

From: Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations

Marker

HHT versus controls

CCM versus controls

Sporadic BAVM versus controls

PI

95% CI

p value

q-value

PI

95% CI

p value

q-value

PI

95% CI

p value

q-value

ANG2

0.51

(0.24, 1.11)

0.089

1.000

0.52

(0.18, 1.49)

0.224

1

1.13

(0.30, 4.19)

0.857

1

BMP9

0.78

(0.28, 2.18)

0.629

1

0.94

(0.28, 3.14)

0.926

1

0.61

(0.11, 3.54)

0.581

1

sCD73

0.70

(0.41, 1.19)

0.188

1

0.67

(0.33, 1.35)

0.261

1

0.68

(0.29, 1.59)

0.373

1

sENG

0.56

(0.45, 0.69)

< 0.001

< 0.001

0.75

(0.59, 0.97)

0.027

0.620

0.85

(0.71, 1.03)

0.101

0.613

GP130

1.00

(0.89, 1.12)

0.996

1

0.93

(0.81, 1.05)

0.234

1

0.79

(0.69, 0.91)

0.001

0.010

HGF

2.42

(1.25, 4.66)

0.008

0.190

1.47

(0.84, 2.58)

0.182

1

3.56

(1.28, 9.88)

0.015

0.123

sICAM1

0.92

(0.80, 1.06)

0.263

1

0.98

(0.83, 1.17)

0.859

1

0.82

(0.69, 0.96)

0.017

0.127

IL6

1.65

(1.07, 2.55)

0.022

0.407

3.22

(2.08, 4.98)

< 0.001

< 0.001

3.12

(1.97, 4.94)

< 0.001

< 0.001

sIL6R

0.94

(0.79, 1.11)

0.465

1

0.88

(0.69, 1.11)

0.272

1

0.62

(0.47, 0.83)

0.001

0.013

OPN

0.99

(0.80, 1.24)

0.954

1

1.33

(1.01, 1.73)

0.039

0.706

0.84

(0.64, 1.12)

0.243

1

PDGF-AA

0.84

(0.53, 1.35)

0.479

1

0.84

(0.48, 1.47)

0.547

1

0.42

(0.29, 0.61)

< 0.001

< 0.001

PDGF-BB

1.17

(0.77, 1.76)

0.466

1

1.63

(0.95, 2.80)

0.075

1

0.69

(0.39, 1.23)

0.210

1

PIGF

1.26

(1.02, 1.57)

0.035

0.526

1.15

(0.84, 1.58)

0.395

1

1.40

(0.90, 2.19)

0.139

0.788

SDF1

1.87

(1.34, 2.62)

< 0.001

0.011

1.53

(0.91, 2.57)

0.106

1

1.62

(0.80, 3.28)

0.180

0.960

TGFβ1

0.98

(0.77, 1.24)

0.856

1

1.40

(1.11, 1.76)

0.005

0.140

0.56

(0.49, 0.64)

< 0.001

< 0.001

TGFβ2

0.95

(0.76, 1.19)

0.682

1

0.93

(0.72, 1.19)

0.547

1

0.76

(0.58, 0.99)

0.045

0.292

sTGFβR3

0.87

(0.73, 1.05)

0.142

1

0.70

(0.57, 0.86)

0.001

0.029

0.59

(0.49, 0.73)

< 0.001

< 0.001

TIMP1

0.96

(0.80, 1.16)

0.700

1

0.93

(0.76, 1.15)

0.518

1

0.65

(0.53, 0.81)

< 0.001

0.002

TSP2

0.85

(0.66, 1.10)

0.213

1

0.78

(0.58, 1.06)

0.109

1

0.64

(0.48, 0.85)

0.002

0.018

sVCAM1

0.97

(0.83, 1.14)

0.709

1

0.92

(0.74, 1.13)

0.423

1

0.71

(0.57, 0.90)

0.004

0.041

VEGF

0.84

(0.56, 1.26)

0.401

1

1.05

(0.69, 1.60)

0.822

1

0.83

(0.57, 1.23)

0.359

1

sVEGFR1

2.96

(1.44, 6.07)

0.003

0.095

1.15

(0.95, 1.39)

0.152

1

3.60

(1.62, 8.01)

0.002

0.018

sVEGFR2

0.97

(0.80, 1.18)

0.776

1

1.01

(0.80, 1.27)

0.938

1

0.71

(0.54, 0.95)

0.020

0.142

sVEGFR3

0.86

(0.73, 1.01)

0.065

0.845

0.98

(0.80, 1.21)

0.858

1

0.90

(0.69, 1.19)

0.471

1

  1. CI confidence interval; PI proportional increase
  2. Bold values indicate markers with a q-value less than 0.05. Sample sizes vary from 53 to 62 for HHT versus controls, 31 to 57 for CCM versus controls, and 25 to 30 for Sporadic BAVM versus controls
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172